Title: Validation of Fine Needle Aspiration Cytology in the Evaluation of Human Epidermal Growth Factor Receptor-2 and Hormonal Receptor Expression Patterns in Breast Cancer Patients
Authors: Osale Christine, Dr Mungania Mary, Dr Mutinda C. Kyama
DOI: https://dx.doi.org/10.18535/jmscr/v7i1.189
Abstract
Introduction: Breast cancer is defined as a group of malignant neoplasms and accounts for up to 22% of all female cancers. It rarely occurs in men. In breast cancer, the level of human epidermal growth factor receptor-2 (HER2) over expression is said to be a prognostic molecular marker that is used for selection of patients for targeted HER2- therapy. Estrogen receptor (ER) and progesterone receptor (PR) are both prognostic and predictive markers for response to hormonal therapy. Fine-needle aspiration (FNA) provides highly cellular sample. Assessment of HER2, ER and PR status in FNA samples is very important clinically. The study was aimed to validate that fine needle aspiration cytology can be used to assess HER2, ER and PR expression patterns in patients with breast cancer.
Methods: Cell blocks were prepared from FNA material collected from 39 newly diagnosed breast cancer patients and immunocytochemistry (ICC) for HER2 and the hormonal receptors, ER and PR was done. Immunohistochemistry (IHC) for HER2, ER and PR was also done on the corresponding biopsy sections. Both positive and negative quality controls were included in the experiments. The Allred scoring system was used to determine the positivity for PR and ER. The overexpression of HER2 was assessed using a scale of 0-3+ for both proportion and intensity whereby 3+ and above was considered positive. The cell block results were compared with core biopsy results and breast cancer classified into various types as luminal A, luminal B, HER2 over expression and the triple negative. The results were then compared with those of core biopsy immunohistochemistry using ANOVA. Kappa statistics was done to check the level of agreement.
Results: Cell block and biopsy results were compared, for ER there was a concordance of 32/35(91.4%) r=0.842 Sensitivity of 83.3% and specificity of 85.0%. For PR the concordance was 32/35(91.4%) r=0.842 with sensitivity of 84.2% and specificity of 84.2%. For HER2 the concordance was 34/35 (97.1%) r=0.925 with a sensitivity of 88.9% and a specificity of 96.3%/. There was moderate agreement between the two methods, k=0.719, p<0.001
Conclusion: The results obtained from FNA cell blocks are reliable when compared with pairedparaffin embeddedtissue blocks. Therefore, HER2, ER and PR can be adequately assessed using cell blocks prepared from FNA material.
Keywords: Fine needle aspiration cytology (FNA), Immunocytochemistry (ICC), Immunohistochemisty (IHC),human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), progesterone receptor (PR), breast cancer
References
- Veronesi U, Boyle P, Goldhirsch A et al. Breast cancer. Lancet, 2005; 365: 1727-41.
- Bray F, Ren JS, Masuyer Eet al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013; 132:1133–1145.
- American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010.
- Cervical cancer summary report update. September, 15: 2010.
- Blackwell KL, Burstein HJ, Storniolo A M et al Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J ClinOncol2010; 28: 1124–30.
- Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of theHER-2/neu Science 1987; 235: 177-182.
- Yokota J, Yamamoto T, Toyoshima K et al. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1986; 1: 765–7.
- Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J ClinOncol 2010; 28: 2784-2795.
- Strasser Weippl K and Goss PE. Advances in adjuvant hormonal therapy for postmenopausal women. J ClinOncol 2005; 23: 1751–1759.
- Wolff AC, Hammond ME, Hicks DG et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med. 2014; 138: 241–256.
- Senkus E, Kyriakides S, Penault-Llorca F et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24: Vi7-23.
- Bird PA, Hill AG, Houssami N. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Ann SurgOncol 2008; 15:1983–8.
- Nizzoli R, Bozzetti C, Naldi Net al. Comparison of the results of immunocytochemical assays for biologic variables on preoperative fine-needle aspirates and on surgical specimens of primary breast carcinomas. Cancer Cytopathol 2000; 90: 61–66.
- Chang J, Elledge RM. Clinical management of women with genomic BRCA1 and BRCA2 mutations. Breast Cancer Res Treat2001; 69:101-113.
- Nyagol J, Kisato V, Ochuk Wet al. Assessment of hormonal receptors and Her2/neu status in breast cancer using cell block: a case study. Afr Cancer 2013; 5: 180-184.
- Kumar SK, Gupta N, Rajwanshi A et al. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma. Cytopathol 2012; 23:181–186
- Kyama M, Mungania et al. Evaluation of human epidermal growth factor receptor-2 and hormonal receptor expression patterns in breast cancer from fine needle aspiration cytologyJournal of Medical Science and Clinical ResearchJuly2018; 6: 675-683
- Nishimura R et al. HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimen. Diagnostic cytopathology Jan 2016 10: 274-279